跳到主要导航 跳到搜索 跳到主要内容

Isobavachin attenuates osteoclastogenesis and periodontitis-induced bone loss by inhibiting cellular iron accumulation and mitochondrial biogenesis

  • Ting Li
  • , Yangge Du
  • , Hantao Yao
  • , Boxuan Zhao
  • , Zijun Wang
  • , Rourong Chen
  • , Yaoting Ji*
  • , Minquan Du*
  • *此作品的通讯作者

科研成果: 期刊稿件 › 论文 › 同行评审

20 引用 (Scopus)

摘要

As bone-resorbing cells rich in mitochondria, osteoclasts require high iron uptake to promote mitochondrial biogenesis and maintain a high-energy metabolic state for active bone resorption. Given that abnormal osteoclast formation and activation leads to imbalanced bone remodeling and osteolytic bone loss, osteoclasts may be crucial targets for treating osteolytic diseases such as periodontitis. Isobavachin (IBA), a natural flavonoid compound, has been confirmed to be an inhibitor of receptor activator of nuclear factor kappa B ligand (RANKL)induced osteoclast differentiation from bone marrow -derived macrophages (BMMs). However, its effects on periodontitis-induced bone loss and the potential mechanism of its anti-osteoclastogenesis effect remain unclear. Our study demonstrated that IBA suppressed RANKL-induced osteoclastogenesis in BMMs and RAW264.7 cells and inhibited osteoclast-mediated bone resorption in vitro. Transcriptomic analysis indicated that iron homeostasis and reactive oxygen species (ROS) metabolic process were enriched among the differentially expressed genes following IBA treatment. IBA exerted its anti-osteoclastogenesis effect by inhibiting iron accumulation in osteoclasts. Mechanistically, IBA attenuated iron accumulation in RANKL-induced osteoclasts by inhibiting the mitogen-activated protein kinase (MAPK) pathway to upregulate ferroportin1 (Fpn1) expression and promote Fpn1-mediated intracellular iron efflux. We also found that IBA inhibited mitochondrial biogenesis and function, and reduced RANKL-induced ROS generation in osteoclasts. Furthermore, IBA attenuated periodontitis-induced bone loss by reducing osteoclastogenesis in vivo. Overall, these results suggest that IBA may serve as a promising therapeutic strategy for bone diseases characterized by osteoclastic bone resorption.
源语言英语
期刊论文编号116202
页数18
期刊Biochemical Pharmacology
卷224
早期在线日期4月 2024
DOI
出版状态已出版 - 6月 2024

基金资助

The work was supported by grants from the National Natural Science Foundation of China (Grant No. 82172493, 82372463, 81771084, 81700772) .

关键词

  • Osteoclast
  • Bone loss
  • Isobavachin
  • Iron accumulation
  • Mitochondrial biogenesis

收录

  • SCIE
  • Scopus

学术指纹

探究 'Isobavachin attenuates osteoclastogenesis and periodontitis-induced bone loss by inhibiting cellular iron accumulation and mitochondrial biogenesis' 的科研主题。它们共同构成独一无二的学术指纹。

引用此